Lung cancer remains one of the deadliest types of cancer. For advanced stages like what Mr. Abdulmalik experienced, over 80% of patients do not survive more than 5 years, with an average survival time of just 2.5 years. There are not many alternative treatments available, and he was advised to use ECCT. His doctor was the first physician to accept ECCT. Mr. Abdulmalik is the first person to use ECCT for a case of lung cancer and has now surpassed 10 years.
Right: Initial CT scan results, after 1 month, 1 year, and 3 years of use; Left: Photo of Mr. Abdulmalik at the 5-year and 10-year marks.
In late October 2011, Mr. Abdulmalik began experiencing bloody coughs. When the condition didn’t improve, he eventually consulted a pulmonologist at a major hospital in Semarang.
The CT scan results strongly indicated lung cancer. The scan showed a nodule measuring 2.8×2.4 cm with calcification, signaling malignancy activity, along with possible spread in the form of infiltrates around it.
He was given medication and advised to undergo another CT scan after one month. After taking the medication for a month, the mass had grown from 2.8×2.4 cm to 4.4×4.2 cm. There was also spread in the form of infiltrates around the mass and lymph nodes near the trachea, which caused more difficulty breathing. The cancer was staged at 3-4 and suspected to be adenocarcinoma.
His doctor did not recommend chemotherapy. The doctor explained that chemotherapy wouldn’t help much, while its side effects and costs were significant. However, his doctor continued to search for a solution for Mr. Abdulmalik.
At the start of 2012, there was significant controversy surrounding ECCT. Warsito had developed the technology initially as a chemotherapy alternative for his sister, Mrs. Suwarni, who had stage 4 breast cancer in 2010. Mrs. Suwarni had undergone surgery but chose not to have chemotherapy, instead using the ECCT device. She achieved remission in 2 months and has since lived cancer-free.
Amid the heated controversy over ECCT in early 2012, Mr. Abdulmalik’s doctor became the first physician to accept ECCT. He recommended that Mr. Abdulmalik use the ECCT device as a chemotherapy alternative.
Mr. Abdulmalik followed his doctor’s advice and began using ECCT. Before starting, he signed an informed consent form, as the device was still in development. Mr. Abdulmalik became the first user of ECCT for lung cancer. In addition to using the device, he was also prescribed oral chemotherapy.
Initially, his sputum production increased, but the amount of blood in his coughs gradually decreased. After about one month, the bleeding had mostly stopped.
A CT scan after one month of ECCT use (March 2012) showed a significant reduction in the mass, shrinking from 4 cm in December 2011 to 2 cm. The structure of the mass also changed, appearing less solid and more like remnants of a melting object.
The process of cancer cell death in adenocarcinoma due to ECCT use resembles the melting of a solid object like ice. Tumor shrinkage occurs as dead cells melt and are expelled from the body through sputum, sweat, urine, and stool. This differs from tumor shrinkage caused by chemotherapy, where the reduction is often due to a decrease in inflammation, rather than the actual death of cancer cells.
However, not all types of adenocarcinoma are the same. The melting (lysis) of the tumor mass only occurs in poorly differentiated (diffuse) or moderately differentiated adenocarcinomas. In well-differentiated adenocarcinomas, dead tumor cells contain a lot of fat or cholesterol, making it harder for them to be expelled, and they may accumulate around the initial tumor mass during the first 3-4 months, causing the mass to grow in volume during the first 3-6 months. In such cases, surgical resection may be beneficial if possible, and ECCT can be used to clean up any remaining cells post-surgery.
In Mr. Abdulmalik’s case, the mass continued to shrink in the following months, but at a slower rate. Subsequent CT scans taken every 3 months showed no significant changes, and after one year of ECCT use, the mass remained stable.
Mr. Abdulmalik’s overall condition continued to improve with ECCT use. After the bloody coughs stopped, his breathing became easier, and he reported no other significant complaints. One year after starting ECCT, he appeared completely healthy, showing no signs of illness, let alone lung cancer. A CT scan after 3 years of ECCT use revealed that only scar tissue remained in the area of the original mass. Cancer cell death and tissue repair occur naturally with ECCT therapy.
Lung cancer remains one of the deadliest types of cancer, especially diffuse types like Mr. Abdulmalik’s. Statistically, the 5-year survival rate for advanced stages is below 10-15%, meaning over 80% of patients do not survive more than 5 years, with an average survival time of just 2.5 years.
Mr. Abdulmalik’s general condition stands in stark contrast to that of most lung cancer patients. He continues to use ECCT as a preventive measure. The device also helps improve blood circulation, keeping his cell and organ metabolism healthy. Over 10 years since first using ECCT, Mr. Abdulmalik’s body appears strong and fit, even in his 60s. He looks much younger than his actual age. In addition to killing cancer cells, ECCT may also rejuvenate normal cells.
We wish Mr. Abdulmalik continued good health.
